| Bioactivity | Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies[1]. |
| Invitro | Ipilimumab 抑制 CTLA-4，使 T 细胞免疫反应对肿瘤细胞重新激活。Ipilimumab 可作为单剂或与细胞因子、化疗或疫苗联合使用，促进抗肿瘤活性[1]。Ipilimumab (0，5 or 50 μg/ mL, 6 days) 单独使用可增强 IL-2 的产生，与 nivolumab 联合使用可刺激外周血单核细胞（PBMC）中更高的 IL-2 释放。而 ipilimumab 和 nivolumab 联合治疗可协同增强效应性和记忆性 T 细胞反应[2]。 |
| In Vivo | Ipilimumab（静脉注射，3 或10mg/kg，每周一次，持续 4 周）联合 nivolumab（10 或 50mg/kg）导致食蟹猴的胃肠道炎症，并与白蛋白减少、球蛋白增加、中性粒细胞和嗜酸性粒细胞计数增加以及大肠单核炎症有关。高剂量组表现为反复腹泻，其胰腺中的腺泡细胞也有明显的脱颗粒现象[2]。 |
| Name | Ipilimumab |
| CAS | 477202-00-9 |
| Molar Mass | 145313.36 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. [2]. Mark J Selby, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779. |